TXMD News and Press, TherapeuticsMD Inc. From 03/03/21

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: TherapeuticsMD, Inc. 2020 Q4 - Results - Earnings Call Presentation

Ovid Therapeutics (OVID) +73% after soticlestat deal with Takeda.KemPharm (KMPH) +69% on FDA approval of ADHD drug.Ocugen, Inc. (OCGN) +39% on Indian partner’s COVID-19 vaccine efficacy data.Asensus Surgical (TRXC) +33% on FDA clearance for Senhance Surgical System....

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q4 2020 Earnings Call Mar 02, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q4 2020 Earnings Call Transcript

TherapeuticsMD, Inc. (TXMD) Q4 2020 Earnings Conference Call March 2, 2021 08:30 ET Company Participants Nichol Ochsner - Vice President of Investor Relations Robert Finizio - Chief Executive Officer James D'Arecca - Chief Financial Officer Dawn Halkuff - Chief Commercial Officer Mitchell Kra...

Therapeutics MD (TXMD) posted fourth-quarter revenue that beat Wall Street estimates, driven by higher demand for its ANNOVERA  system (segesterone acetate and ethinyl estradiol vaginal system).ANNOVERA net product revenue increased 42% to $9.1M for the fourth quarter of 2020 as compared...

Therapeutics MD (TXMD): Q4 GAAP EPS of -$0.15 misses by $0.05.Revenue of $22.6M (+42.1% Y/Y) beats by $0.89M.Shares +9.34% PM.Press Release For further details see: Therapeutics MD EPS misses by $0.05, beats on revenue

- Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 - - 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q20 - - ANNOVERA ® net product revenue increased 42% for 4Q20 compared to 3Q20 - - Financing Agr...

-Executive Management to Host Conference Call on March 2, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2020 financial results on Tuesday, March 2, 2021, before t...

TherapeuticsMD (TXMD) has priced an underwritten public offering of 59.5 million shares for net proceeds of $110M.Proceeds to be used for commercialization of its three FDA-approved products, Imvexxy, Bijuva, and Annovera; partial proceeds also for offering to discharge certain indebtedness c...

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million, before deducting the underwriting discounts and commissions and other estimated offering expens...